XML 50 R38.htm IDEA: XBRL DOCUMENT v3.25.1
Segment Reporting (Tables)
3 Months Ended
Mar. 31, 2025
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information, by Segment
Net income for our segment was as follows (in thousands):
Three Months Ended
March 31,
20252024
Product revenues, net922,274 729,923 
Product royalty revenues130,624 125,966 
Milestone and contract revenues— 25,000 
Total revenues1,052,898 880,889 
Costs, expenses and other:
Cost of product revenues (including definite-lived intangible amortization)73,188 60,956 
Research and development - internal1
228,345 223,096 
Research and development - external2
193,434 205,164 
Other research and development3
15,500 1,000 
Sales and marketing257,652 216,813 
General and administrative68,039 83,443 
Loss (gain) on change in fair value of acquisition-related contingent consideration11,572 (456)
(Profit) and loss sharing under collaboration agreements— (1,025)
Other segment items4
46,965 (77,650)
Net income$158,203 169,548 

1.Research and development - internal is comprised of internally generated costs such as salaries, travel, regulatory costs, lab costs, contracting, etc.
2.Research and development - external is comprised of specific program spend with external vendors (i.e. contract manufacturing organization, contract research organization and lab vendors for clinical, technical operations and toxicology services).
3.Other research and development is comprised of all other costs including certain one-time costs resulting from the acquisition of IPR&D assets and one-time development milestone expenses.
4.Other segment items is comprised of interest income, interest expense, realized and unrealized (gain) loss on equity investments, other, net, and provision for income taxes.